We focus on both Asian cohorts and diseases to build up an epigenomic database that serves as a platform for novel drug and biomarker discoveries. We further develop proprietary pan-cancer epigenomic predictive models to deliver clinical insights that are complementary to genomic information today.

Our flagship clinical product, EPI-CALL™, reports epigenomic information for patients and identifies probability of response to immunotherapy. It is complementary with current Next Generation Sequencing (NGS) tests and does not require additional Formalin Fixed Paraffin Embedded (FFPE) slides. Through EPI-CALL™, we empower clinicians to make better treatment decisions for their patients.

Through our research service Signomax™, a proprietary ChIP-Seq process that is compatible with both FFPE slides and fresh frozen tissues, we advance, accelerate, and drive epigenomic research endeavours.